Evidence map›Paper›PMID 40711886›Full record

ArticleOncotarget2025

Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.

Aiden Deacon, Ava Gustafson, Allison Makovec, Ella Boytim, Gabriella von Dohlen, David Moline, Elin Kairies, Sam Kellen, Khalid Ishani, Megan L Ludwig and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aiden DeaconDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Ava GustafsonDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Allison MakovecDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Ella BoytimDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Gabriella von DohlenDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
David MolineDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Elin KairiesCornell College, Mount Vernon, IA 52314, USA.
Sam KellenDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Khalid IshaniDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Megan L LudwigDepartment of Pharmacology, University of Minnesota- Twin Cities, Minneapolis, MN 55455, USA.
Emily JohnDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Alexis AnikeDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Hai Dang NguyenDepartment of Pharmacology, University of Minnesota- Twin Cities, Minneapolis, MN 55455, USA.
Scott M DehmDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Justin M DrakeDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Emmanuel S AntonarakisDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Justin HwangDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Implications of PARP1 in myelodysplastic syndromes and targeted therapyR01HL163011 · NHLBI · UNIVERSITY OF MINNESOTA · PI Dang Hai Nguyen · 2022 to 2026
$2.5M
RET Regulation and Targeting in Neuroendocrine Prostate CancerR01CA269801 · NCI · UNIVERSITY OF MINNESOTA · PI Justin Michael Drake · 2022 to 2026
$2.2M
Targeting early events in prostate cancer lineage plasticityR01CA270539 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2023 to 2026
$1.8M
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)R37CA288972 · NCI · UNIVERSITY OF MINNESOTA · PI Justin H. Hwang · 2024 to 2026
$1.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA269801NCI NIH HHS R01 CA270539NCI NIH HHS R37 CA288972NHLBI NIH HHS R01 HL163011
6 · The paper itself

Abstract

This study investigates the R-spondin family of genes (

Indexed as

Prostatic NeoplasmsThrombospondinsbeta CateninCell Line, TumorEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansIntercellular Signaling Peptides and ProteinsMaleNeoplasm MetastasisReceptors, AndrogenR-SpondinsWnt Signaling Pathwaybeta CateninCTNNB1 protein, humanIntercellular Signaling Peptides and ProteinsReceptors, AndrogenRspo2 protein, humanR-SpondinsThrombospondinsgenomicsprostate cancerRSPO2therapeuticsWnt signaling

Identifiers

PMID40711886
PMCPMC12406459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.